Meeting News Coverage

Study: Fixed-combination glaucoma treatment shows better rate of adherence

COPENHAGEN, Denmark — A 6-month trial comparing fixed-combination therapy vs. concomitant unfixed glaucoma treatment found that patients who received fixed-combination treatment had a higher rate of compliance to eye drops.

“This study has documented a significantly greater adherence rate and ocular surface health with fixed compared with unfixed combination therapy in patients treated for open-angle glaucoma or ocular hypertension. This trial has provided, for the first time, verification for the benefits of fixed combination therapy on adherence and ocular surface health,” Anastasios G.P. Konstas, MD, PhD, and colleagues said in a poster study presented here at the European Glaucoma Society meeting.

The prospective 6-month parallel observational study examined results of 142 patients divided into two groups; 71 patients received Xalacom (latanoprost/timolol, Pfizer) once in the evening, and 71 received Xalatan (latanoprost, Pfizer) once in the evening and timolol twice daily.

Konstas and colleagues found a negative correlation between dosing and adherence, with patients who received fewer drops fewer times per day more likely to adhere to their drop regimen.

  • Disclosure: The study was supported in part by an unrestricted grant from Pfizer. Konstas is a consultant for Alcon, Allergan and MSD. He is a researcher for Alcon, Allergan, MSD and Pfizer.

COPENHAGEN, Denmark — A 6-month trial comparing fixed-combination therapy vs. concomitant unfixed glaucoma treatment found that patients who received fixed-combination treatment had a higher rate of compliance to eye drops.

“This study has documented a significantly greater adherence rate and ocular surface health with fixed compared with unfixed combination therapy in patients treated for open-angle glaucoma or ocular hypertension. This trial has provided, for the first time, verification for the benefits of fixed combination therapy on adherence and ocular surface health,” Anastasios G.P. Konstas, MD, PhD, and colleagues said in a poster study presented here at the European Glaucoma Society meeting.

The prospective 6-month parallel observational study examined results of 142 patients divided into two groups; 71 patients received Xalacom (latanoprost/timolol, Pfizer) once in the evening, and 71 received Xalatan (latanoprost, Pfizer) once in the evening and timolol twice daily.

Konstas and colleagues found a negative correlation between dosing and adherence, with patients who received fewer drops fewer times per day more likely to adhere to their drop regimen.

  • Disclosure: The study was supported in part by an unrestricted grant from Pfizer. Konstas is a consultant for Alcon, Allergan and MSD. He is a researcher for Alcon, Allergan, MSD and Pfizer.

    See more from European Glaucoma Society Congress 2012